Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 141 to 150 of 279 total matches.

Atogepant (Qulipta) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
the onset of menses.3 MECHANISM OF ACTION — CGRP is a potent vasodilator and pain-signaling ...
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-71 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
pruritus, dermatitis and pain, muscle spasms, insomnia, abdominal pain, constipation, diarrhea ...
View the Comparison Table: Drugs for Alzheimer's Disease
Med Lett Drugs Ther. 2022 Aug 22;64(1657):e136-7 |  Show IntroductionHide Introduction

In Brief: RSV Vaccine (Arexvy) for Ages 50-59

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
years old within 4 days of receiving Arexvy were injection-site pain (75.8%), erythema (13.2 ...
The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old. Two other RSV vaccines have received FDA approval: Abrysvo, a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants, and mResvia, an mRNA vaccine recently licensed for use in adults ≥60 years old...
Med Lett Drugs Ther. 2024 Jul 22;66(1707):113-4   doi:10.58347/tml.2024.1707a |  Show IntroductionHide Introduction

Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
, headache, nausea, fatigue, abdominal pain, vomiting, GI erosion, dizziness, dyspnea, arteriovenous ...
The FDA has approved the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) vadadustat (Vafseo – Akebia) for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 3 months. Vadadustat is the second HIF-PHI to be approved in the US for this indication; daprodustat (Jesduvroq) was approved earlier, but it was withdrawn from the US market in 2024 for commercial reasons.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):27-9   doi:10.58347/tml.2025.1722b |  Show IntroductionHide Introduction

Mirikizumab (Omvoh) — An IL-23 Antagonist for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • May 12, 2025  (Issue 1728)
to achieve a clinical response (a ≥30% decrease in stool frequency or abdominal pain) at week 12 ...
The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis. Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya), are also approved for treatment of CD.
Med Lett Drugs Ther. 2025 May 12;67(1728):78-80   doi:10.58347/tml.2025.1728d |  Show IntroductionHide Introduction

Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
, decreased appetite, musculoskeletal pain, decreased albumin, constipation, dyspnea, decreased sodium ...
The alkylating agent lurbinectedin (Zepzelca – Jazz) has received accelerated approval from the FDA for treatment of metastatic small-cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. About 13-15% of lung cancers are small-cell cancers. Most SCLCs occur in patients who are current or former smokers.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e198-9 |  Show IntroductionHide Introduction

Capmatinib (Tabrecta) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
EFFECTS — Capmatinib can cause edema, musculoskeletal pain, fatigue, vomiting, dyspnea, cough ...
The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases. The drug received accelerated approval for the same indication in 2020 based on initial overall response rates and duration of response.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e65-6   doi:10.58347/tml.2023.1674d |  Show IntroductionHide Introduction

Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
, rhinitis, and dyspepsia. Priapism and low back pain can also occur. Acute hearing loss, with or without ...
A reader asked us to review use of the phosphodiesterase-5 (PDE5) inhibitor sildenafil for treatment of Alzheimer's disease (AD).
Med Lett Drugs Ther. 2022 Oct 31;64(1662):174-5 |  Show IntroductionHide Introduction

In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
, lymphopenia, dizziness, and abdominal pain were also reported. DRUG INTERACTIONS — Olaparib is metabolized ...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone (Zytiga, and others) and either prednisone or prednisolone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib was previously approved by the FDA for treatment of adults with deleterious or suspected deleterious germline or somatic homologous recombinant repair (HRR) genemutated mCRPC who progressed on prior treatment with...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7   doi:10.58347/tml.2023.1679g |  Show IntroductionHide Introduction

Osimertinib (Tagrisso) for Adjuvant Treatment of NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
EFFECTS — Diarrhea, rash, musculoskeletal pain, dry skin, stomatitis, fatigue, and cough are common ...
The FDA has approved osimertinib (Tagrisso – AstraZeneca), an oral kinase inhibitor, for adjuvant treatment of non-small cell lung cancer (NSCLC) after tumor resection in adults who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Osimertinib is the first targeted therapy to be approved in the US for this indication. The drug was previously approved for first-line treatment of adults with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations and for treatment of EGFR T790M mutation-positive NSCLC in adults whose disease progressed...
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e131-2   doi:10.58347/tml.2023.1682c |  Show IntroductionHide Introduction